Teva Pharmaceutical Industries Ltd. — Director's Dealing 2021

Feb 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2021-02-09

Reporting Person: Stark David Matthew (Exec. VP Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Ordinary Shares	M	12538	—	Acquired	15512.39	Direct
2021-02-09	Ordinary Shares	A	52774	—	Acquired	68286.39	Direct
2021-02-09	Ordinary Shares	S	12538	$12.6945	Disposed	55748.39	Direct
2021-02-09	Ordinary Shares	S	52774	$12.6945	Disposed	2974.39	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Restricted Share Units	$	M	12538	Disposed		Ordinary Shares (12538)	Direct
2021-02-09	Restricted Share Units	$	A	37884	Acquired		Ordinary Shares (37884)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.

F4: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.

F5: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F7: Restricted share units were granted on February 9, 2018, with 12,538 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F8: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to
time-based vesting and will vest on May 11, 2021.